MRK-409, also known as MK-0343, is a GABAA receptor partial agonist.[1]
It was designed to be a non-sedative anxiolytic, however its development was halted because it produced sedation in humans.[2]
Pharmacodynamics
Despite lacking the benzodiazepine chemical structure, MRK-409 acts on the benzodiazepine binding site, it is therefore a nonbenzodiazepine.
MRK-409 binds to the α1, α2, α3 and α5 subunits of the GABAA receptor.[3]
In rats, it produces minimal to no sedation, however it produces sedation in humans at doses above 1 mg.[2][4]
References
- ↑ "MRK-409" (in en). https://go.drugbank.com/drugs/DB13993.
- ↑ 2.0 2.1 Atack, John R. (2010). "GABAA Receptor α2/α3 Subtype-Selective Modulators as Potential Nonsedating Anxiolytics". GABAA receptor alpha2/alpha3 subtype-selective modulators as potential nonsedating anxiolytics. Current Topics in Behavioral Neurosciences. 2. pp. 331–360. doi:10.1007/7854_2009_30. ISBN 978-3-642-02911-0.
- ↑ Atack, J. R.; Wafford, K. A.; Street, L. J.; Dawson, G. R.; Tye, S.; Van Laere, K.; Bormans, G.; Sanabria-Bohórquez, S. M. et al. (2011). "MRK-409 (MK-0343), a GABAA receptor subtype-selective partial agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in humans". Journal of Psychopharmacology 25 (3): 314–328. doi:10.1177/0269881109354927. ISSN 1461-7285. PMID 20147571.
- ↑ Atack, J. R.; Hallett, D. J.; Tye, S.; Wafford, K. A.; Ryan, C.; Sanabria-Bohórquez, S. M.; Eng, Wai-Si; Gibson, R. E. et al. (2011). "Preclinical and clinical pharmacology of TPA023B, a GABAA receptor α2/α3 subtype-selective partial agonist". Journal of Psychopharmacology 25 (3): 329–344. doi:10.1177/0269881109354928. ISSN 1461-7285. PMID 20156926.
|
|---|
| Alcohols | |
|---|
| Barbiturates | |
|---|
| Benzodiazepines | |
|---|
| Carbamates | |
|---|
| Flavonoids | |
|---|
| Imidazoles | |
|---|
| Kava constituents | |
|---|
| Monoureides | |
|---|
| Neuroactive steroids | |
|---|
| Nonbenzodiazepines | |
|---|
| Phenols | |
|---|
| Piperidinediones | |
|---|
| Pyrazolopyridines | |
|---|
| Quinazolinones | |
|---|
| Volatiles/gases | |
|---|
| Others/unsorted |
- 3-Hydroxybutanal
- α-EMTBL
- AA-29504
- Avermectins (e.g., ivermectin)
- Bromide compounds (e.g., lithium bromide, potassium bromide, sodium bromide)
- Carbamazepine
- Chloralose
- Chlormezanone
- Clomethiazole
- DEABL
- Dihydroergolines (e.g., dihydroergocryptine, dihydroergosine, dihydroergotamine, ergoloid (dihydroergotoxine))
- DS2
- Efavirenz
- Etazepine
- Etifoxine
- Fenamates (e.g., flufenamic acid, mefenamic acid, niflumic acid, tolfenamic acid)
- Fluoxetine
- Flupirtine
- Hopantenic acid
- Lanthanum
- Lavender oil
- Lignans (e.g., 4-O-methylhonokiol, honokiol, magnolol, obovatol)
- Loreclezole
- Menthyl isovalerate (validolum)
- Monastrol
- Niacin
- Nicotinamide (niacinamide)
- Org 25,435
- Phenytoin
- Propanidid
- Retigabine (ezogabine)
- Safranal
- Seproxetine
- Stiripentol
- Sulfonylalkanes (e.g., sulfonmethane (sulfonal), tetronal, trional)
- Terpenoids (e.g., borneol)
- Topiramate
- Valerian constituents (e.g., isovaleric acid, isovaleramide, valerenic acid, valerenol)
|
|---|
|
 | Original source: https://en.wikipedia.org/wiki/MRK-409. Read more |